>>Signaling Pathways>> Membrane Transporter/Ion Channel>> VDAC>>WEHI-9625

WEHI-9625

Catalog No.GC62641

WEHI-9625는 삼환식 설폰으로 EC50이 69nM인 동급 최초의 세포자멸사 억제제입니다. WEHI-9625는 VDAC2에 결합하고 마우스 BAK에 의해 구동되는 세포자멸사를 억제하는 능력을 촉진합니다. WEHI-9625는 인간 BAK와 밀접하게 관련된 세포자멸사 효과기 BAX에 대해 완전히 비활성입니다.

Products are for research use only. Not for human use. We do not sell to patients.

WEHI-9625 Chemical Structure

Cas No.: 2595314-46-6

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$588.00
재고 있음
5 mg
US$450.00
재고 있음
10 mg
US$765.00
재고 있음
25 mg
US$1,620.00
재고 있음
50 mg
US$2,700.00
재고 있음
100 mg
US$4,140.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WEHI-9625 is a tricyclic sulfone, first-in-class inhibitor of apoptosis with an EC50 of 69 nM. WEHI-9625 binds to VDAC2 and promotes its ability to inhibit apoptosis driven by mouse BAK. WEHI-9625 is completely inactive against both human BAK and the closely related apoptosis effector BAX[1].

WEHI-9625 (0-10 µM; Mcl1-/-Bax-/- MEFs cells) treatment could prevent cell death mediated by BAK and potently inhibits BIM BH3-induced loss of mitochondrial membrane potential in Bax-/-, but not Bak-/-, cells[1].

WEHI-9625 demonstrates that blocking apoptosis at an early stage was both advantageous and pharmacologically tractable[1].

[1]. van Delft MF, et al. A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. Nat Chem Biol. 2019 Oct 7.

리뷰

Review for WEHI-9625

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WEHI-9625

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.